IL139455D0 - Compounds for the treatment of female sexual dysfunction - Google Patents

Compounds for the treatment of female sexual dysfunction

Info

Publication number
IL139455D0
IL139455D0 IL13945500A IL13945500A IL139455D0 IL 139455 D0 IL139455 D0 IL 139455D0 IL 13945500 A IL13945500 A IL 13945500A IL 13945500 A IL13945500 A IL 13945500A IL 139455 D0 IL139455 D0 IL 139455D0
Authority
IL
Israel
Prior art keywords
compounds
treatment
sexual dysfunction
female sexual
female
Prior art date
Application number
IL13945500A
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB9926437A priority Critical patent/GB9926437D0/en
Priority to GB0004021A priority patent/GB0004021D0/en
Priority to GB0013001A priority patent/GB0013001D0/en
Priority to GB0016563A priority patent/GB0016563D0/en
Priority to GB0017141A priority patent/GB0017141D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of IL139455D0 publication Critical patent/IL139455D0/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027New breeds of vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-arylpropionic acids, ethacrynic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/107Rabbit
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
IL13945500A 1999-11-08 2000-11-02 Compounds for the treatment of female sexual dysfunction IL139455D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB9926437A GB9926437D0 (en) 1999-11-08 1999-11-08 Pharmaceutical
GB0004021A GB0004021D0 (en) 2000-02-18 2000-02-18 Pharmaceutical
GB0013001A GB0013001D0 (en) 2000-05-26 2000-05-26 Pharmaceutical
GB0016563A GB0016563D0 (en) 2000-07-05 2000-07-05 Pharmaceutical
GB0017141A GB0017141D0 (en) 2000-07-12 2000-07-12 Pharmaceutical

Publications (1)

Publication Number Publication Date
IL139455D0 true IL139455D0 (en) 2001-11-25

Family

ID=27515922

Family Applications (4)

Application Number Title Priority Date Filing Date
IL13945700A IL139457D0 (en) 1999-11-08 2000-11-02 Compounds for the treatment of female sexual dysfunction
IL13945500A IL139455D0 (en) 1999-11-08 2000-11-02 Compounds for the treatment of female sexual dysfunction
IL13945600A IL139456D0 (en) 1999-11-08 2000-11-02 Compounds for the treatment of female sexual dysfunction
IL13945400A IL139454D0 (en) 1999-11-08 2000-11-02 Compounds for the treatment of female sexual dysfunction

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL13945700A IL139457D0 (en) 1999-11-08 2000-11-02 Compounds for the treatment of female sexual dysfunction

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL13945600A IL139456D0 (en) 1999-11-08 2000-11-02 Compounds for the treatment of female sexual dysfunction
IL13945400A IL139454D0 (en) 1999-11-08 2000-11-02 Compounds for the treatment of female sexual dysfunction

Country Status (24)

Country Link
US (1) US6734186B1 (en)
EP (5) EP1097706A1 (en)
JP (9) JP2001213802A (en)
KR (7) KR20010086267A (en)
CN (5) CN1636597A (en)
AT (1) AT285249T (en)
AU (6) AU7140900A (en)
BR (3) BR0005266A (en)
CA (4) CA2323183A1 (en)
CO (2) CO5680109A1 (en)
CZ (3) CZ20004107A3 (en)
DE (1) DE60016877T2 (en)
DK (1) DK1097719T3 (en)
EA (3) EA006254B1 (en)
ES (1) ES2233297T3 (en)
HU (4) HU0004350A2 (en)
IL (4) IL139457D0 (en)
MY (2) MY140534A (en)
NO (3) NO20005661L (en)
NZ (4) NZ508011A (en)
PE (4) PE20010817A1 (en)
PL (3) PL343753A1 (en)
PT (1) PT1097719E (en)
SK (3) SK16722000A3 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
DK172900B1 (en) 1998-12-18 1999-09-27 Per Julius Nielsen Preparation and kit for use in intraocular operations
US20050070499A1 (en) * 1999-11-08 2005-03-31 Pfizer Inc. Compounds for the treatment of female sexual dysfunction
US20020052370A1 (en) * 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
IL155775D0 (en) * 2000-12-15 2003-12-23 Pfizer Treatment of male sexual dysfunction
US6660756B2 (en) 2001-03-28 2003-12-09 Pfizer Inc. N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
HU0303624A3 (en) 2001-03-28 2005-06-28 Pfizer N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad and process for preparation of the compounds
GB0111709D0 (en) * 2001-05-14 2001-07-04 Pfizer Ltd Novel pharmaceuticals
AR037097A1 (en) 2001-10-05 2004-10-20 Novartis Ag Acylsulfonamides compounds, pharmaceutical compositions and use of said compounds for the preparation of a medicament
HN2002000317A (en) * 2001-11-02 2003-05-21 Pfizer PDE9 inhibitors for treating cardiovascular disorders
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
JP2006519243A (en) * 2003-03-04 2006-08-24 アルタナ ファルマ アクチエンゲゼルシャフトALTANA Pharma AG Purin-6-one derivative
EP1617888B1 (en) 2003-04-23 2019-06-12 Valeritas, Inc. Hydraulically actuated pump for long duration medicament administration
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US7427611B2 (en) 2003-09-26 2008-09-23 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7452875B2 (en) 2003-09-26 2008-11-18 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7262184B2 (en) 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US20050267072A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
WO2005123119A2 (en) * 2004-06-10 2005-12-29 Catalyst Biosciences, Inc. Administration of neutral endopeptidase to treat inflammatory bowel disease
WO2006014425A1 (en) 2004-07-02 2006-02-09 Biovalve Technologies, Inc. Methods and devices for delivering glp-1 and uses thereof
ES2313626T3 (en) 2005-03-21 2009-03-01 Pfizer Limited Triazol derivatives substituted as an oxitocine antagonists.
JP2009532117A (en) 2006-03-30 2009-09-10 ヴァレリタス,エルエルシーValeritas,Llc Multi-cartridge fluid dispensing device
KR20090042227A (en) 2006-06-06 2009-04-29 인트라-셀룰라 써래피스, 인코퍼레이티드. Organic compounds
JP5701608B2 (en) 2007-12-06 2015-04-15 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. Organic compounds
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
US8650937B2 (en) 2008-09-19 2014-02-18 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
CA2740396A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
PE20110944A1 (en) 2008-12-06 2012-01-25 Intra Cellular Therapies Inc Pyrazolo [3,4-d] PYRIMIDINE AS INHIBITORS PDE1
AU2009322899A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
WO2010132127A1 (en) 2009-05-13 2010-11-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2011011312A1 (en) 2009-07-22 2011-01-27 Merck Sharp & Dohme Corp. Quinolinone pde2 inhibitors
EP2932994B1 (en) 2009-07-30 2017-11-08 Tandem Diabetes Care, Inc. New o-ring seal, and delivery mechanism and portable infusion pump system related thereto
JP5894148B2 (en) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. Organic compounds
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
CN104822368B (en) * 2011-12-05 2019-01-11 苏达公司 Silaenafil mouthspray preparation and its medication
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
JP6549040B2 (en) 2013-02-17 2019-07-24 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. New use
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9815796B2 (en) 2013-12-23 2017-11-14 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as PDE2 inhibitors
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
EP3177627B1 (en) 2014-08-07 2019-07-24 Intra-Cellular Therapies, Inc. Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-one derivatives with pde1 inhibiting activity
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
US10287269B2 (en) 2015-03-26 2019-05-14 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as PDE2 inhibitors
US10195201B2 (en) 2015-05-05 2019-02-05 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as PDE2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
KR880007441A (en) * 1986-12-11 1988-08-27 알렌 제이.스피겔 Spiro-substituted glutaric amide diuretic
US4749717A (en) * 1987-01-08 1988-06-07 Smithkline Beckman Corporation Dopamine-beta-hydroxylase inhibitors
AU6522590A (en) * 1989-09-18 1991-04-18 Senetek Plc Method for inducing vaginal lubrication
US5380758A (en) 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5612314A (en) 1995-04-21 1997-03-18 Brigham & Women's Hospital Nitrosylated neuropeptides
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
DE19541264A1 (en) * 1995-11-06 1997-05-07 Bayer Ag Purin-6-one derivatives
WO1997020821A1 (en) * 1995-12-01 1997-06-12 Novartis Ag Heteroaryl derivatives
US5798246A (en) 1996-03-25 1998-08-25 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterase
GB9608408D0 (en) * 1996-04-23 1996-06-26 Adams Michael A Treatment of erectile dysfunction
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
DK0915859T3 (en) * 1996-07-23 2003-03-03 Neurogen Corp Certain substituted benzylamine derivatives; a new class of Neuropeptide Y1-specific ligands
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US20020004529A1 (en) * 1997-10-20 2002-01-10 Gary W. Neal Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US5965718A (en) * 1997-10-24 1999-10-12 The Scripps Research Institute Analogs of sarcodictyin and eleutherobin
GB9722520D0 (en) * 1997-10-24 1997-12-24 Pfizer Ltd Compounds
EP1027057A4 (en) * 1997-10-28 2003-01-02 Vivus Inc Treatment of female sexual dysfunction
AUPP010397A0 (en) * 1997-10-30 1997-11-20 Vaisman, Jakov Method and composition for treatment of sexual dysfunction
ID25871A (en) * 1997-11-12 2000-11-09 Bayer Ag Imidazotriazinon substituted-2-phenyl
AU1025899A (en) 1998-09-16 2000-04-03 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
US6486207B2 (en) * 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US20020169101A1 (en) * 1999-05-10 2002-11-14 Gonzalez Maria Isabel Treatment of sexual dysfunction
US20020052370A1 (en) * 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase

Also Published As

Publication number Publication date
AU781403B2 (en) 2005-05-19
JP2001206855A (en) 2001-07-31
CZ20004110A3 (en) 2002-04-17
DE60016877D1 (en) 2005-01-27
EA200001042A3 (en) 2002-04-25
KR20040074022A (en) 2004-08-21
PL343755A1 (en) 2001-05-21
EA200001043A3 (en) 2002-04-25
EP1481667A1 (en) 2004-12-01
PE20010925A1 (en) 2001-09-17
AU7140700A (en) 2001-05-17
CN1636597A (en) 2005-07-13
CZ20004106A3 (en) 2002-04-17
EA006242B1 (en) 2005-10-27
HU0004348A2 (en) 2001-06-28
JP2005013237A (en) 2005-01-20
PT1097719E (en) 2005-04-29
AU7140800A (en) 2001-05-17
JP2005350482A (en) 2005-12-22
JP2001247479A (en) 2001-09-11
JP2001213802A (en) 2001-08-07
DE60016877T2 (en) 2005-12-15
AU2005202166A1 (en) 2005-06-16
AU7141100A (en) 2001-05-10
CA2323191A1 (en) 2001-05-08
EP1097719B1 (en) 2004-12-22
HU0004350D0 (en) 2001-01-29
EP1097718A1 (en) 2001-05-09
AU7140900A (en) 2001-05-10
HU0004347A2 (en) 2001-06-28
IL139456D0 (en) 2001-11-25
HU0004350A2 (en) 2001-06-28
SK16702000A3 (en) 2002-07-02
BR0005276A (en) 2003-04-08
NZ508012A (en) 2002-06-28
NO20005661L (en) 2001-05-09
JP2005070055A (en) 2005-03-17
HU0004349D0 (en) 2001-01-29
PE20010817A1 (en) 2001-08-14
KR20010051481A (en) 2001-06-25
NO20005618L (en) 2001-05-09
NO20005662L (en) 2001-05-09
AU781400B2 (en) 2005-05-19
NO20005662D0 (en) 2000-11-07
HU0004347D0 (en) 2001-01-29
EP1097707A1 (en) 2001-05-09
HU0004348D0 (en) 2001-01-29
AT285249T (en) 2005-01-15
CA2323464A1 (en) 2001-05-08
PE20010926A1 (en) 2001-09-15
EA200001044A2 (en) 2001-12-24
CZ20004107A3 (en) 2002-04-17
EP1097706A1 (en) 2001-05-09
NZ508007A (en) 2002-06-28
AU781186B2 (en) 2005-05-12
PL343754A1 (en) 2001-05-21
IL139454D0 (en) 2001-11-25
IL139457D0 (en) 2001-11-25
EA200001042A2 (en) 2001-12-24
HU0004349A2 (en) 2001-06-28
EA200001043A2 (en) 2001-12-24
CO5680108A1 (en) 2006-09-29
JP2001247478A (en) 2001-09-11
DK1097719T3 (en) 2005-03-29
PL343753A1 (en) 2001-05-21
NZ508006A (en) 2002-06-28
BR0005299A (en) 2003-04-15
CA2324484A1 (en) 2001-05-08
ES2233297T3 (en) 2005-06-16
BR0005266A (en) 2003-04-08
CO5680109A1 (en) 2006-09-29
CN1322526A (en) 2001-11-21
CN1575816A (en) 2005-02-09
PE20010924A1 (en) 2001-09-13
NO20005661D0 (en) 2000-11-07
SK16712000A3 (en) 2002-07-02
CN1328824A (en) 2002-01-02
NZ508011A (en) 2002-06-28
EP1097719A1 (en) 2001-05-09
MY140534A (en) 2009-12-31
JP2005021167A (en) 2005-01-27
EA006254B1 (en) 2005-10-27
US6734186B1 (en) 2004-05-11
CA2323183A1 (en) 2001-05-08
KR20040074021A (en) 2004-08-21
KR20010086267A (en) 2001-09-10
MY141651A (en) 2010-05-31
EA200001044A3 (en) 2002-04-25
SK16722000A3 (en) 2002-09-10
AU2005202750A1 (en) 2005-07-21
JP2005043377A (en) 2005-02-17
KR20040074023A (en) 2004-08-21
NO20005618D0 (en) 2000-11-07
KR20010082544A (en) 2001-08-30
KR20010082545A (en) 2001-08-30
CN1320426A (en) 2001-11-07

Similar Documents

Publication Publication Date Title
DE60019556D1 (en) 2-amino-benzoxazine derivatives for the treatment of fatibility
DK0967214T3 (en) Intranasal formulations for the treatment of sexual disorders
DE60028358D1 (en) Hmg1 antagonists for the treatment of inflammation
DE50009504D1 (en) Use of retigabin for the treatment of neuropathic pain
DE60031396D1 (en) Preparation for the treatment of a neurological disease
GB2368019B (en) Apparatus for electrical stimulation of the body
DE69940131D1 (en) Agent for the treatment of diseases of the esophagus
DE69911448D1 (en) Pyrazolopyrimidinone, cgmp pde5 inhibitors, for the treatment of sexual functional disorders
GB2351661B (en) Novel method of treatment
DE69925970D1 (en) Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction
DE69936335D1 (en) Use of morpholinol for the treatment of sexual functional disorders
DE69933128D1 (en) Pharmaceutical compositions for the treatment of effective dysfunction
DE60109274D1 (en) Prostagland-based compositions for the treatment of male impotence
MXPA03004815A (en) Use of bisphosphonates for pain treatment.
IL146394A (en) Generation of therapeutic microfoam
DE60130007D1 (en) Compositions and methods for treating the female sexual reaction
DE60019555D1 (en) 2-oxy-benzoxazinone derivatives for the treatment of fatibility
IL143661A (en) Compositions for amelioration of human female sexual dysfunction
EP1274444A4 (en) Compounds for the treatment of psychiatric or substance abuse disorders
RU2005122932A (en) Benzazepine derivatives for the treatment of neurological disorders
DE60016877D1 (en) NEP inhibitors for the treatment of female sexual disorders
HRP20040678A2 (en) Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders
IL156784D0 (en) 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
ZA200202461B (en) Compounds for the treatment of ischemia.
HK1056498A1 (en) Controlled impotence treatment